Filing summary
Entity and period: The supplied filing is a Form 10-Q for Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.). It covers the unaudited three months ended June 30, 2016, compared with the three months ended June 30, 2015. The company describes itself as a specialty pharmaceutical business focused on dermatology and advanced tissue care.
Financial performance and liquidity
- Revenue: $3.811 million, up 4% from $3.680 million. Product revenue rose 20% to $3.509 million; licensing fees and royalties fell 83% to $75,000; service revenue declined to $227,000 from $317,000.
- Geographic product revenue: United States increased 74% to $1.373 million; Europe and Rest of World increased 82% to $1.038 million; Latin America decreased 30% to $1.098 million.
- Profit and margins: Gross profit was $1.919 million, or 50% of revenue, versus $1.873 million, or 51%. Product gross margin improved to 51% from 48%. Operating expenses rose to $4.490 million from $4.184 million. Operating loss was $2.571 million and net loss was $2.568 million, compared with a $2.340 million net loss. Basic and diluted loss per share was $0.61 versus $0.77; share and per-share amounts reflect a 1-for-5 reverse split.
- Cash flow: Operating cash use was $2.377 million, compared with $2.585 million. Investing activities used $11,000 and financing activities used $48,000. Cash decreased $2.499 million during the quarter, to $4.970 million at June 30.
- Liquidity and debt: Working capital was $6.965 million, down from $9.337 million at March 31, 2016. The balance sheet reports $66,000 of current long-term debt and $3.570 million of total liabilities; it lists no noncurrent debt balance. Accumulated deficit was $154.943 million.
Changes, outlook and risks
- U.S. and international product growth was partly offset by weaker Latin American sales, which management attributed to peso depreciation and prior-year partner stocking. The decline in licensing revenue mainly reflected lower amortization of upfront payments from Laboratorios Sanfer.
- Management attributed higher SG&A to sales and marketing costs, including expansion of the U.S. dermatology sales force and new product launches. It expects SG&A to increase as the sales force grows. Management said it intends to launch Lasercyn over the following nine months and expects continuing losses for the foreseeable future.
- The company states it may need additional capital and that financing may not be available on acceptable terms, if at all. It warns that failure to raise capital could require spending cuts, delay commercialization and impair its ability to sustain operations. The filing says these conditions raise substantial doubt about the company’s ability to continue as a going concern; the financial statements include no related adjustments.
- One customer accounted for 29% of quarterly net revenue. At quarter-end, one customer represented 41% of net accounts receivable, and three others represented 11% each.
- The company effected a 1-for-5 reverse stock split on June 24, 2016. It disclosed potential severance payments of $1.194 million under key-executive employment agreements if triggered. A new CEO employment agreement was entered into on July 26, 2016. Management reported disclosure controls were effective and no material change in internal control over financial reporting. No material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Confirm the issuer: this filing names Oculus Innovative Sciences, Inc., while the request identifies Sonoma Pharmaceuticals, Inc.
- Assess the company’s cash runway, near-term funding needs and ability to obtain financing, in light of quarterly operating cash use and the disclosed going-concern uncertainty.
- Check whether U.S. dermatology growth and improved product margins can offset higher selling costs and declines in Latin America and licensing revenue.
- Review customer concentration and receivables exposure, as well as the timing and terms of any subsequent financing or material commercial developments.